SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
Company profile
Ticker
SIBN
Exchange
Website
CEO
Jeffrey Dunn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
SI-Bone Inc.
SEC CIK
Corporate docs
Subsidiaries
SI-BONE S.R.L. • SI-BONE Deutschland GmbH • SI-BONE UK LTD ...
IRS number
262216351
SIBN stock data
Analyst ratings and price targets
Current price
Average target
$23.25
Low target
$18.00
High target
$32.00
Truist Securities
Maintains
$21.00
Morgan Stanley
Maintains
$18.00
JMP Securities
Maintains
$32.00
Needham
Maintains
$22.00
Latest filings (excl ownership)
8-K
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022
9 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance
7 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
SI-BONE, Inc. Reports First Quarter 2022 Financial Results
9 May 22
DEF 14A
Definitive proxy
22 Apr 22
S-8
Registration of securities for employees
1 Mar 22
Transcripts
SIBN
Earnings call transcript
2022 Q3
8 Nov 22
SIBN
Earnings call transcript
2022 Q2
9 Aug 22
SIBN
Earnings call transcript
2022 Q1
9 May 22
SIBN
Earnings call transcript
2021 Q4
1 Mar 22
SIBN
Earnings call transcript
2021 Q3
9 Nov 21
SIBN
Earnings call transcript
2021 Q2
3 Aug 21
SIBN
Earnings call transcript
2021 Q1
4 May 21
SIBN
Earnings call transcript
2020 Q4
9 Mar 21
SIBN
Earnings call transcript
2020 Q3
2 Nov 20
SIBN
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm | 26.30 mm |
| Cash burn (monthly) | (no burn) | 2.80 mm | 4.52 mm | 5.19 mm | 2.18 mm | 3.97 mm |
| Cash used (since last report) | n/a | 11.45 mm | 18.51 mm | 21.23 mm | 8.90 mm | 16.23 mm |
| Cash remaining | n/a | 14.85 mm | 7.79 mm | 5.07 mm | 17.39 mm | 10.07 mm |
| Runway (months of cash) | n/a | 5.3 | 1.7 | 1.0 | 8.0 | 2.5 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 111 |
| Opened positions | 13 |
| Closed positions | 14 |
| Increased positions | 36 |
| Reduced positions | 39 |
| 13F shares | Current |
|---|---|
| Total value | 692.64 mm |
| Total shares | 37.72 mm |
| Total puts | 10.10 k |
| Total calls | 24.90 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Brown Advisory | 3.73 mm | $65.16 mm |
| Orbimed Advisors | 3.37 mm | $58.81 mm |
| BLK Blackrock | 2.74 mm | $47.90 mm |
| Orbimed Capital | 2.31 mm | $51.20 mm |
| First Light Asset Management | 2.03 mm | $35.41 mm |
| Champlain Investment Partners | 1.80 mm | $31.43 mm |
| Vanguard | 1.61 mm | $28.06 mm |
| Arboretum Ventures IV | 1.55 mm | $46.27 mm |
| Holocene Advisors | 1.44 mm | $25.13 mm |
| Point72 Asset Management | 1.30 mm | $22.77 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Jan 23 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | Yes | 16.08 | 284 | 4.57 k | 237,901 |
| 17 Jan 23 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | Yes | 16.01 | 1,000 | 16.01 k | 238,185 |
| 17 Jan 23 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | No | 16.2041 | 664 | 10.76 k | 239,185 |
| 17 Jan 23 | Pisetsky Michael A | Common Stock | Sell | Dispose S | No | No | 16.1821 | 399 | 6.46 k | 172,108 |
| 17 Jan 23 | Dunn Jeffrey W | Common Stock | Sell | Dispose S | No | No | 16.1435 | 1,739 | 28.07 k | 101,992 |
| 6 Jan 23 | Anshul Maheshwari | Common Stock | Grant | Acquire A | No | No | 0 | 19,159 | 0.00 | 166,124 |
| 6 Jan 23 | Anshul Maheshwari | Common Stock | Grant | Acquire A | No | No | 0 | 57,478 | 0.00 | 146,965 |
| 6 Jan 23 | Pisetsky Michael A | Common Stock | Grant | Acquire A | No | No | 0 | 56,445 | 0.00 | 172,507 |
News
Where SI-BONE Stands With Analysts
31 Jan 23
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $21
31 Jan 23
Expert Ratings for SI-BONE
6 Jan 23
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18
6 Jan 23
SI-BONE Announces FDA Clearance For Expanded Rod Compatibility With The iFuse Bedrock Granite Implant System
27 Dec 22
Press releases
SI-BONE to Host a Virtual Fireside Chat at the 25th Annual Needham Growth Conference
3 Jan 23
SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite® Implant System
27 Dec 22
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance
7 Nov 22